177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence
<sup>177</sup>Lu-PRRT appears to be an effective therapy with a good safety profile for patients with metastatic PPGL. It also appears to improve HRQoL in patients with metastatic PPGL. Further studies are needed to explore the most effective treatment modalities in this group of patients and their sequencing.
Authors
- Bernard Chong Eu Khoo (ORCID: https://orcid.org/0000-0002-4223-9736)
- Shaunak Navalkissoor (ORCID: https://orcid.org/0000-0003-2886-9691)
- Dalvinder Mandair (ORCID: https://orcid.org/0000-0002-5237-8641)
- Christos Toumpanakis (ORCID: https://orcid.org/0000-0002-1152-7727)
- Martyn Caplin (ORCID: https://orcid.org/0000-0003-0177-1352)
- Kalyan Mansukhbhai Shekhda (ORCID: https://orcid.org/0000-0001-7884-0403)
- Dominic Yu (ORCID: https://orcid.org/0009-0005-3174-1391)
- Ashley Barry Grossman (ORCID: https://orcid.org/0000-0003-1176-6186)
- Eleni Armeni (ORCID: https://orcid.org/0000-0003-3310-1521)
- Aimee R. Hayes (ORCID: https://orcid.org/0000-0003-4417-7716)
- Gopinath Gnanasegaran
- Manfredi d’Afflitto (ORCID: https://orcid.org/0000-0001-6347-0219)
- Yiwang Xu (ORCID: https://orcid.org/0000-0002-0429-7572)
- Ann‐Marie Quigley
Institutions
- The Royal Free Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-25-0019
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 0.00